Curated News
By: NewsRamp Editorial Staff
October 05, 2026
Oncotelic's PDAOAI Invites BIO REBOOT Participants, Sets Keynotes
TLDR
- Oncotelic's PDAOAI invites BIO REBOOT participants to secure startup funding and expert support for drug discovery projects.
- PDAOAI uses AI search aggregation and Partitioned Literature Aggregation to generate candidate gene signatures for drug discovery.
- Oncotelic's PDAOAI platform aims to accelerate drug discovery for cancers and rare pediatric diseases, improving patient outcomes.
- BIO REBOOT lets scientists and founders bring research questions to PDAOAI for potential funding and development support.
Impact - Why it Matters
This news matters because it signals a growing trend of integrating artificial intelligence into early-stage drug discovery, potentially shortening timelines and reducing costs. Oncotelic's PDAOAI platform, through initiatives like BIO REBOOT, offers a unique opportunity for researchers and startups to gain funding and developmental support, which could accelerate the creation of novel therapies for cancers with high unmet need. The upcoming keynotes at a major drug discovery conference further validate the platform's capabilities and may attract broader industry collaboration. For investors, this underscores Oncotelic's commitment to innovation and could enhance its long-term value proposition in the competitive biotech landscape.
Summary
Oncotelic Therapeutics (OTCQB: OTLC) and its wholly owned subsidiary Pet2DAO, Inc. have issued an open invitation to scientists, AI developers, and biotech founders to join BIO REBOOT, an initiative powered by Oncotelic's PDAOAI artificial intelligence-driven drug discovery platform. Participants are encouraged to bring research questions, technical expertise, and drug discovery ideas to the PDAOAI community. Selected projects may receive startup funding and comprehensive support from Oncotelic, including validation, formulation, regulatory planning, and clinical development. This collaborative push aims to accelerate the translation of AI insights into viable therapeutic candidates.
In addition, Oncotelic announced that two PDAOAI keynote presentations will be delivered at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for October 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study that demonstrates how Partitioned Literature Aggregation generated a candidate four-gene signature. Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development. These talks underscore PDAOAI's potential to streamline target identification and drug development workflows. For the complete press release, visit https://ibn.fm/dxB7y.
Oncotelic Therapeutics develops oncology and immunotherapy products, focusing on cancers with substantial unmet needs and rare pediatric indications. The company also develops the PDAOAI platform to support its drug discovery and development efforts. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC. This announcement was distributed through BioMedWire (BMW), a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BMW is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions via InvestorWire and more.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic's PDAOAI Invites BIO REBOOT Participants, Sets Keynotes
